Screener
Ginkgo Bioworks DNA Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
FAQ
- What is Ginkgo Bioworks's deferred revenue?
- Ginkgo Bioworks (DNA) reported deferred revenue of $13.21M in Q2 2026.
- How has Ginkgo Bioworks's deferred revenue changed year-over-year?
- Ginkgo Bioworks's deferred revenue decreased by 53.3% year-over-year, from $28.29M to $13.21M.
- What is the long-term trend for Ginkgo Bioworks's deferred revenue?
- Over 5 years (2020 to 2025), Ginkgo Bioworks's deferred revenue has grown at a -28.3% compound annual growth rate (CAGR), from $99.65M to $18.95M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Ginkgo Bioworks's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude